

PATENT APPLICATION No.: 10/672,077
ATTORNEY DOCKET: 62611.000235

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/672,077 Confirmation No.: 4735
Applicant : Linda ARTERBURN, et al.
Filed : September 29, 2003
Title : GLYCEMIC CONTROL FOR PREDIABETES AND/OR DIABETES
TYPE II USING DOCOSAHEXAENOIC ACID
TC/Art Unit : 1614
Examiner: : Unassigned

Docket No. : 62611.000235
Customer No. : 21967

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

The attached documents were cited by the European Patent Office in the Supplementary Partial European Search Report dated March 14, 2006 of the corresponding application and relevance as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

For each foreign language document for which no translation is available, the document was cited by the European Examiner in the Search Report of the corresponding application and relevance as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.


Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: May 5, 2006

By: 
Robert C. Lampe, III
Registration No. 51,914

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
RCL/asc



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/672,077
		Filing Date	September 29, 2003
		First Named Inventor	Linda ARTERBURN, et al.
		Art Unit	1614
		Examiner Name	Unassigned
Sheet	1 of 1	Attorney Docket Number	62611.000235

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code	Number-Kind Code (if known)				YES	NO
	1.	DE	100 56 351 A1	05-29-2002	Weylandt		<input type="checkbox"/>	<input type="checkbox"/>
	2.	JP	60-248610 A	12-09-1985	Kondo		<input type="checkbox"/>	<input type="checkbox"/>
	3.	WO	99/04782	02-04-1999	Horrobin, et al.		<input type="checkbox"/>	<input type="checkbox"/>
	4.	WO	00/44862 A	08-03-2000	Mag		<input type="checkbox"/>	<input type="checkbox"/>
	5.	WO	02/43659 A2	06-06-2002	Bendich		<input type="checkbox"/>	<input type="checkbox"/>
	6.	WO	02/072119 A	09-19-2002	Vuksan		<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	7.	Malasanos, et al., "Biological Effects of Omega-3 Fatty Acids in Diabetes Mellitus", Diabetes Care, Vol. 14, No. 12, pg. 1160-1179, December 1991.	<input type="checkbox"/>	<input type="checkbox"/>
	8.	Pepping, "Alternative Therapies Omega-3 Essential Fatty Acids", Am. J. Health-Syst. Pharm., Vol. 56, No. 8, pg. 719-720 and 723-724, April 15, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	9.	Nosari, et al., "Impiego Degli Omega-3 Nel Paziente Diabetico", Clinica Terapeutica, Societa Editrice Unierso, Rome, Italy, Vol. 144, No. 3, pg. 213-221, March 1994.	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	10.	Montori, et al., "Fish Oil Supplementation in Type 2 Diabetes", Diabetes Care, Vol.23, No. 9, pg. 1407-1415, September 2000.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.